Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MHC class I ligandome of CT26 cells

ABSTRACT: MS data of MHC class I ligandome of CT26, a mouse colon cancer line

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Takayuki Kanaseki

PROVIDER: PXD029094 | JPOST Repository | Tue Nov 30 00:00:00 GMT 2021

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ST646_CT26_Dd_1.mgf	Mgf
	ST646_CT26_Dd_1.raw	Raw
	ST646_CT26_Dd_2.mgf	Mgf
	ST646_CT26_Dd_2.raw	Raw
	ST646_CT26_Dd_3.mgf	Mgf

Items per page:

1 - 5 of 8

Similar Datasets

MHC class I ligandome of cells treated with palladium

Project description:MHC class I ligandome analysis of mouse dendritic cells treated with palladium

2021-12-16 | PXD028795 | JPOST Repository

HLA class II ligandome of colon cancer tissues for neoantigen identification

Project description:MS data of HLA class II ligandome of human colon cancer tissues

| PXD054060 | JPOST Repository

HLA class I ligandome of colon cancer tissues for neoantigen identification

Project description:MS data of HLA class I ligandome of human colon cancer tissues

| PXD026573 | JPOST Repository

HLA class I ligandome of colon cancer tissues for lncRNA antigen identification

Project description:MS data of HLA class I ligandome of human colon cancer tissues

| PXD024533 | JPOST Repository

Tumour-associated antigenic peptides are present in the HLA class I ligandome of cancer cell line derived extracellular vesicles.

Project description:The recent success of monoclonal antibody checkpoint inhibitor therapies that enhance the ability of CD8+ T cells to detect cancer-related antigenic peptides has refocused the need to fully understand the repertoire of peptides being presented to the immune system. Whilst the peptide ligandome presented by cell surface HLA class I molecules on cancer cells has been studied extensively, the ligandome of extracellular vesicles remains poorly defined. Here we report the HLA class I ligandome of both cell surface and extracellular vesicles from eight breast cancer cell lines (MCF7, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, HCC 1806, HCC 1395, and HCC 1954), and additionally the melanoma cell line ESTDAB-056 and the multiple myeloma line RPMI 8226. Utilising HLA class I immunoisolation and mass spectrometry we detected a total of 6574 peptides from the cell surface and 2461 peptides from the extracellular vesicles of the cell lines studied. Within the extracellular vesicle HLA class I ligandome we identified 150 peptides derived from tumour associated antigenic proteins, of which 19 peptides have been shown to elicit T cell responses in previous studies. Our data thus confirms for the first time the presence of clinically relevant tumour-associated antigenic peptides in the HLA class I ligandome present on EV.

2022-04-01 | PXD025345 | Pride

Pre-fractionation extends, but creates a bias in the detectable HLA class Ι ligandome

Project description:HLA class Ι molecules on the cell surface enable CD8+ T lymphocytes to recognize cellular alterations in the form of antigens, including mutations, protein copy number alterations, aberrant post-translational modifications or pathogen proteins. At any given moment, tens of thousands of different self and foreign HLA class Ι peptide ligands may be presented on the cell surface by MHC class Ι complexes. Analysis of the HLA ligandome thrusts therefore unique challenges due to their enormous biochemical diversity and inherently wide range of abundances. Despite advances in enrichment, separation, MS instrumentation and fragmentation, it is still not achievable to cover the HLA class Ι ligandome in sufficient depth to support routine identification of e.g. viral pathogens or immuno-therapeutically important tumor neo-antigens. In this study, we evaluate two pre-fractionation techniques, high pH reversed phase and strong cation exchange for complementary analysis of HLA class Ι peptide ligands, benchmarking them against analyses circumventing pre-fractionation. We observe that pre-fractionation substantially extends the detectable HLA class Ι ligandome, but also creates an identification bias. We advocate a rational choice between no-fractionation, high pH reversed phase or strong cation exchange pre-fractionation for deeper HLA class Ι ligandome analysis depending on the targeted HLA locus, allele or peptide ligand modification

2019-02-25 | PXD011257 | Pride

Mapping the HLA ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation

Project description:Immunopeptidome analysis of colorectal adenocarcinoma tissues as well as adjacent benign tissues was performed to characterize the natural HLA class I and class II presented ligandome represented in the context of malignancy as well as in benign tissue of the colon.

2019-03-12 | PXD009602 | Pride

HLA class I ligandome of renal cancer tissues for hERV antigen identification

Project description:MS data of HLA class I ligandome of human renal cancer tissues

2023-11-15 | PXD038140 | JPOST Repository

Zapnometinib treatment and influenza A virus infection induce alteration on the HLA class I ligandome of human lung adenocarcinoma cells

Project description:Targeting cellular factors is considered a promising approach to combat viral infection and overcome the resistance issue associated with direct-acting antiviral (DAA) drugs administration. In the context of drug repurposing strategies, we have previously explored the antiviral efficacy of the MEK inhibitor zapnometinib against influenza virus and SARS-CoV-2. Herein, since zapnometinib was originally promoted as an anti-cancer drug, we aimed to investigate the impact of zapnometinib on the HLA class I ligandome post-treatment and IAV infection. By implementing the immunopeptidomics approach, the influence on the HLA-I allotype distribution of the HLA ligands was observed to coincide with alteration in the relative abundance of HLA-I-presented peptides. Furthermore, functional annotation analysis of the corresponding source proteins of presented ligands revealed a remarkable gene enrichment of distinct cellular processes. Taken together, zapnometinib and IAV showed a remarkable effect on the HLA-I ligandome plasticity as well as quantitative alterations in HLA ligandome composition.

2026-06-15 | PXD041578 | Pride